TASIGNA 200 MG 28 CAPS

Indication For the potential treatment of various leukemias including chronic myeloid leukemia (CML). Pharmacodynamics Nilotinib is a transduction inhibitor that targets BCR-ABL c-kit and PDGF for the potential treatment of various leukemias including chronic myeloid leukemia (CML). Mechanism of action Chronic myelogenous leukaemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein. Nilotinib fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib over-riding resistance caused by mutations. The ability of AMN107 to inhibit TEL-platelet-derived growth factor receptor-beta (TEL-PDGFRbeta) which causes chronic myelomonocytic leukaemia and FIP1-like-1-PDGFRalpha which causes hypereosinophilic syndrome suggests potential use of AMN107 for myeloproliferative diseases characterised by these kinase fusions (Stover et al 2005; Weisberg et al 2005). AMN107 also inhibits the c-Kit receptor k